Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.

The past and future of haemophilia: diagnosis, treatments, and its complications

Abstract

Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and muscle bleeds lead to severe and progressive musculoskeletal damage. Existing treatment relies on replacement therapy with clotting factors, either at the time of bleeding (ie, on demand) or as part of a prophylactic schedule. The major complication of such therapy is the development of neutralising antibodies (ie, inhibitors), which is most frequent in haemophilia A. Treatment might improve considerably with the availability of new modified drugs, which might overcome existing prophylaxis limitations by reducing dosing frequency and thereby rendering therapy less distressing for the patient. Subcutaneous administration of some new therapies would also simplify prophylaxis in children with poor venous access. Gene therapy has the potential for a definitive cure, and important results have been obtained in haemophilia B. Despite improvements in haemophilia care, the availability of clotting factor concentrates for all affected individuals worldwide remains the biggest challenge.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)01123-x

Cites

144 of 144 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 144 references

Research works printed but not linked: 1

  1. Shima, 2015, Long-term safety and prophylactic efficacy of once weekly subcutaneous administration of ACE910, in Japanese hemophilia A patients with and without FVIII inhibitors: interim results of the extension study of a phase 1 study, J Thromb Haemost, 13, 6

Cited by

See all 586

Metadata

Authors
Peyvandi, F., Garagiola, I., & Young, G.
Affiliations
  • University of Milan (IT)
  • University of Southern California (US)
Corresponding author
Peyvandi, Flora
Venue
The Lancet
Publisher
Elsevier BV
Published
2016-07
Volume
388
Issue
10040
Pages
187-197
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2274569134
Cited by
505
References
144
Citations by year
2026: 47 · 2025: 53 · 2024: 57 · 2023: 53 · 2022: 59 · 2021: 60 · 2020: 45 · 2019: 38 · 2018: 37 · 2017: 40 · 2016: 15
FWCI
6.13
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
  • Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
Keywords
hemophilia A, hemophilia B, factor replacement therapy, prophylaxis, on-demand treatment, neutralizing antibodies, inhibitors, subcutaneous administration, gene therapy, musculoskeletal damage
MeSH terms
Hemophilia B, Coagulants, Factor IX, Factor VIII, Hemophilia A, Hemorrhage, Humans, Genetic Therapy, Antibodies, Neutralizing, Early Medical Intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The past and future of haemophilia: diagnosis, treatments, and its complications. https://app.cochat.ai/papers/10.1016/s0140-6736(15)01123-x
The paper
Peyvandi, F., Garagiola, I., & Young, G. (2016). The past and future of haemophilia: diagnosis, treatments, and its complications. The Lancet. https://doi.org/10.1016/s0140-6736(15)01123-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.